Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.

Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH.

Diabet Med. 2013 Sep;30(9):1026-32. doi: 10.1111/dme.12144. Review.

PMID:
23350856
2.

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

Zhu Z, Shen Z, Lu Y, Zhong S, Xu C.

Diabetes Res Clin Pract. 2012 Oct;98(1):159-63. doi: 10.1016/j.diabres.2012.05.006. Epub 2012 Jun 16.

PMID:
22705039
3.

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL.

Diabetes Care. 2011 Apr;34(4):916-22. doi: 10.2337/dc10-1068.

4.

Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.

Fujimoto K, Hamamoto Y, Honjo S, Kawasaki Y, Mori K, Tatsuoka H, Matsuoka A, Wada Y, Ikeda H, Fujikawa J, Koshiyama H.

Diabetes Res Clin Pract. 2013 Feb;99(2):e21-3. doi: 10.1016/j.diabres.2012.11.013. Epub 2012 Dec 7.

PMID:
23228390
5.

Observational follow-up of the PROactive study: a 6-year update.

Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn AR, Perez A.

Diabetes Obes Metab. 2014 Jan;16(1):63-74. doi: 10.1111/dom.12180. Epub 2013 Aug 19.

PMID:
23859428
6.

Pioglitazone and cancer: angel or demon?

Kostapanos MS, Elisaf MS, Mikhailidis DP.

Curr Pharm Des. 2013;19(27):4913-29. Review.

PMID:
23278487
7.

Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.

Korhonen P, Heintjes EM, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S.

BMJ. 2016 Aug 16;354:i3903. doi: 10.1136/bmj.i3903.

8.

Pioglitazone use and the risk of bladder cancer.

Kuo HW, Tiao MM, Ho SC, Yang CY.

Kaohsiung J Med Sci. 2014 Feb;30(2):94-7. doi: 10.1016/j.kjms.2013.09.011. Epub 2013 Oct 29.

9.

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.

Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, Keskimäki I, Badrick E, Renehan AG, Buchan IE, Bowker SL, Minhas-Sandhu JK, Zafari Z, Marra C, Johnson JA, Stricker BH, Uitterlinden AG, Hofman A, Ruiter R, de Keyser CE, MacDonald TM, Wild SH, McKeigue PM, Colhoun HM; Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium.

Diabetologia. 2015 Mar;58(3):493-504. doi: 10.1007/s00125-014-3456-9. Epub 2014 Dec 7.

PMID:
25481707
10.

Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.

Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S.

Clin Drug Investig. 2013 Sep;33(9):621-31. doi: 10.1007/s40261-013-0106-9.

11.

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, Nessel L, Van Den Eeden SK, Ferrara A.

JAMA. 2015 Jul 21;314(3):265-77. doi: 10.1001/jama.2015.7996.

PMID:
26197187
12.

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.

Colmers IN, Bowker SL, Majumdar SR, Johnson JA.

CMAJ. 2012 Sep 4;184(12):E675-83. doi: 10.1503/cmaj.112102. Epub 2012 Jul 3.

13.

Pioglitazone use and risk of bladder cancer: population based cohort study.

Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L.

BMJ. 2016 Mar 30;352:i1541. doi: 10.1136/bmj.i1541.

14.

Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.

He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y.

Tumour Biol. 2014 Mar;35(3):2095-102. doi: 10.1007/s13277-013-1278-x. Epub 2013 Oct 4.

PMID:
24092576
15.

Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.

Lewis JD, Habel L, Quesenberry C, Mamtani R, Peng T, Bilker WB, Hedderson M, Nessel L, Vaughn DJ, Strom BL, Ferrara A.

Pharmacoepidemiol Drug Saf. 2014 Jun;23(6):636-45. doi: 10.1002/pds.3619. Epub 2014 Apr 25.

PMID:
24764283
16.

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.

Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H.

Diabetologia. 2012 Jul;55(7):1953-62. doi: 10.1007/s00125-012-2538-9. Epub 2012 Mar 31.

17.

Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.

Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS.

Drug Saf. 2013 Aug;36(8):643-9.

PMID:
23797604
18.

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.

Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S.

BMJ. 2012 May 30;344:e3645. doi: 10.1136/bmj.e3645.

19.

Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?

Tseng CH.

J Formos Med Assoc. 2012 Mar;111(3):123-31. doi: 10.1016/j.jfma.2011.10.003. Epub 2012 Feb 15. Review.

20.

Meta-analysis confirms raised risk of bladder cancer from pioglitazone.

Kermode-Scott B.

BMJ. 2012 Jul 4;345:e4541. doi: 10.1136/bmj.e4541. No abstract available.

PMID:
22763399

Supplemental Content

Support Center